Advantage : MET-097i Summary and Verdict# MET-097i represents a potentially disruptive approach to GLP-1 therapy with its ultra-long half-life enabling once-monthly dosing
Ongoing mental health assessment during GLP-1 treatment should include regular check-ins about mood, sleep, motivation, and emotional stability
Current clinical evidence does not clearly establish GLP-1 agonists as a direct cause of kidney stones
You are worthy and even if you dont feel worthy yet, I invite you to do it anyway
In the univariable analysis, C5-OH less than 0.22 mol/L was negatively associated with CVD in T2DM, utilizing 0.220.30 mol/L as the reference [OR (95%CI) of C5-OH for 3.0.Co;2-s 18 HouQGuanYYuWLiuXWuLXiaoMet al
It some cases, it may cause increased blood pressure and lowered heart rate